Objective: Chronic graft versus host disease (cGVHD) develops after allogeneic hematopoietic cell transplantation, when immune cells from a non-identical donor initiate an immune reaction against the transplant recipient. Extracorporeal photopheresis (ECP) can be used in combination with prednisone in steroid-resistant cGVHD. In this study, the effect of ECP use on survival in cGVHD was examined. Patients and Methods: Twenty-six patients who were followed up in the adult Hematology Clinic of Inonu University Turgut Ozal Medical Center for cGVHD were included in the study. Stem cell transplantation and ECP application parameters that may affect the survival of the patients were examined. Results: The degree of involvement in cGVHD affects survival. Involvements with clinical and laboratory scores of 2 and above according to the National Institutes of Health consensus criteria, significantly reduced survival. The development time of cGVHD was found to be associated with survival, and that it had a positive impact on survival, especially when the disease developed after 220 days after the transplantation. It was observed that steroid dose taken during ECP, patient age and cGVHD prophylaxis used affected survival. Conclusion: The use of ECP may be effective in survival, especially, in patients who develop cGVHD, 220 days after allogeneic transplantation. Concurrent use of steroids with ECP affects survival.

Aims: In this study, we aim to discover if there is a difference between COVID 19 antibody level in hematological patients taking conventional chemotherapy and tyrosin kinase inhibitors. Methods: COVİD 19 IgG levels were measured using the QuantiCOR anti-SARS-CoV-2 IgG ELISA test kit on 74 patients who received chemotherapy and used tyrosine kinase inhibitors in the adult hematology clinic of Turgut Özal Medical Center between May 2019 and January 2022. Age, height, weight, badimeks index of the patients were measured, the doses and durations of vaccine use, the time between the first vaccine and the second vaccine, how long after the first vaccine antibodies were checked, and vaccine-related side effects were recorded. Collected data Statistical analysis was performed using Python 3.9 and IBM SPSS Statistics for Windows version 26.0 (New York; USA). Results: Antibody levels of the patients were significantly higher in the healthy control group than in the groups that received chemotherapy and tyrosine kinase inhibitors. Antibody levels of female patients in the control group were higher than male patients. Antibody levels of the patient groups receiving chemotherapy and tyrosine kinase inhibitor were not found to differ between the two groups. When the patients receiving B lymphocyte suppressing chemotherapy in the chemotherapy group were compared with the control group, antibody levels were found to be higher in the control group. Conclusion: COVID 19 vaccination in hematological cancers did not produce adequate antibody response, especially in patients receiving chemotherapy or tyrosine kinase inhibitors.